Aduro Biotech, Inc. announced a strategic reset to focus on Aduro's core strengths – discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways. Aduro is partnered with Novartis for STING pathway activators in oncology, including ADU-S100 (MIW815).